Ensysce Biosciences, Inc. Common Stock
ENSC XNASAbout Ensysce Biosciences, Inc. Common Stock
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $493.1K | $-3,729,128 | $-1.29 |
| Q1 2025 | $1.32M | $-1,945,573 | $-1.39 |
| FY 2024 | $5.21M | $-7,987,009 | $-11.45 |
| Q3 2024 | $3.42M | $661.8K | $0.07 |
TickerDaily Coverage
Get ENSC Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Ensysce Biosciences, Inc. Common Stock.